{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:19:40Z","timestamp":1775708380847,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.thromres.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T07:59:07Z","timestamp":1433663947000},"page":"1087-1098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials"],"prefix":"10.1016","volume":"136","author":[{"given":"Sina","family":"Kianoush","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur M.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2015.06.001_bb0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina","volume":"333","author":"Bittl","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2015.06.001_bb0015","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jacc.2012.08.966","article-title":"A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011","volume":"60","author":"Dehmer","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0020","series-title":"Annual Report on Form 10-K for The Fiscal Year Ended December 31, 2012","year":"2013"},{"key":"10.1016\/j.thromres.2015.06.001_bb0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Urgent Intervention Triage strategy trial i. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial","volume":"369","author":"Stone","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2015.06.001_bb0030","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0035","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0040","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2015.06.001_bb0045","series-title":"Scientific Sessions of the American College of Cardiology","article-title":"Novel Approaches in Preventing or Limiting Event III \u2013 randomized comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting through the femoral approach (NAPLES III)","author":"Briguori","year":"2014"},{"key":"10.1016\/j.thromres.2015.06.001_bb0050","first-page":"ehu182","article-title":"Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction","author":"Schulz","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2015.06.001_bb0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2015.06.001_bb0060","article-title":"Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials","author":"Cassese","year":"2014","journal-title":"EuroIntervention"},{"key":"10.1016\/j.thromres.2015.06.001_bb0065","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.amjcard.2009.12.001","article-title":"Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial)","volume":"105","author":"Parodi","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0075","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2015.06.001_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.thromres.2015.06.001_bb0090","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.thromres.2015.06.001_bb0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2015.06.001_bb0100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2015.06.001_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mhj.2002.120405","article-title":"Bivalirudin as a replacement for unfractionated heparin in unstable angina\/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial","volume":"143","author":"Antman","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2015.06.001_bb0110","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","article-title":"Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)","volume":"96","author":"White","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2015.06.001_bb0115","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0120","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/joic.12005","volume":"26","author":"Waksman","year":"2013","journal-title":"J. Interv. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2015.06.001_bb0135","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.amjcard.2009.06.035","article-title":"Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention","volume":"104","author":"Tavano","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0140","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2004.01.033","article-title":"Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)","volume":"93","author":"Lincoff","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0145","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","volume":"110","author":"Patti","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0150","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.amjcard.2011.06.033","article-title":"Effect of Prolonged Bivalirudin Infusion on ST-Segment Resolution Following Primary Percutaneous Coronary Intervention (from the PROBI VIRI 2 Study)","volume":"108","author":"Cortese","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0155","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.3760\/cma.j.issn.0366-6999.20122569","article-title":"Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention","volume":"126","author":"Xiang","year":"2013","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.thromres.2015.06.001_bb0160","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","article-title":"A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic AgentsThe PROTECT\u2013TIMI-30 Trial","volume":"47","author":"Gibson","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0165","series-title":"Transcatheter Cardiovascular Therapeutics Meeting (TCT 2014)","article-title":"BivaliRudin in Acute Myocardial Infarction vs. Glycoprotein IIb\/IIIa and Heparin","author":"Ya-Ling","year":"2014"},{"key":"10.1016\/j.thromres.2015.06.001_bb0170","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non\u2013ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.carrev.2005.06.003","article-title":"Bivalirudin compared with IIb\/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy","volume":"6","author":"Kuchulakanti","year":"2005","journal-title":"Cardiovasc. Revasc. Med."},{"key":"10.1016\/j.thromres.2015.06.001_bb0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ccd.22876","volume":"77","author":"Moliterno","year":"2011","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2015.06.001_bb0185","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ihj.2012.07.022","article-title":"Safety and efficacy of Bivalirudin with Glycoprotein IIb\/IIIa for high-risk percutaneous coronary intervention","volume":"64","author":"Deshpande","year":"2012","journal-title":"Indian Heart J."},{"key":"10.1016\/j.thromres.2015.06.001_bb0190","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jcin.2008.10.004","volume":"1","author":"Lincoff","year":"2008","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"10.1016\/j.thromres.2015.06.001_bb0195","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrcardio.2012.34","article-title":"Anticoagulation therapy: Dabigatran and risk of myocardial infarction","volume":"9","author":"Eikelboom","year":"2012","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.thromres.2015.06.001_bb0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/246355a0","article-title":"Anticoagulant action of heparin","volume":"246","author":"Damus","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2015.06.001_bb0205","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2015.06.001_bb0210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/1740774507079443","article-title":"The role of intention to treat in analysis of noninferiority studies","volume":"4","author":"Wiens","year":"2007","journal-title":"Clin. Trials"},{"key":"10.1016\/j.thromres.2015.06.001_bb0215","first-page":"ehu214","article-title":"Bivalirudin is superior to heparins alone with bailout GP IIb\/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial","author":"Zeymer","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2015.06.001_bb0220","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2010-05-280883","article-title":"Systematic review and meta-analysis methodology","volume":"116","author":"Crowther","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.06.001_bb0225","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N. Engl. J. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481530013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481530013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T13:47:48Z","timestamp":1708782468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938481530013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S004938481530013X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2015.06.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}